SCHEMBL1850211

SCHEMBL1850211

Cc1cccc(NC(=O)Nc2cccc(-c3n[nH]cc3-c3ccncc3)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.60
PKM P14618 1/20 0.60
KMT2A Q03164 1/20 0.60
RIPK1 Q13546 1/20 0.51
IMPDH2 P12268 1/20 0.49
KDR P35968 10/20 0.48
FLT1 P17948 5/20 0.48
FLT4 P35916 5/20 0.48
FLT3 P36888 5/20 0.48
KIT P10721 4/20 0.48
PDGFRA P16234 3/20 0.48
PDGFRB P09619 1/20 0.48
CNR1 P21554 2/20 0.48
GAA P10253 1/20 0.47
CSF1R P07333 4/20 0.47
LCK P06239 3/20 0.47
BLK P51451 2/20 0.47
ABL1 P00519 1/20 0.47
FYN P06241 1/20 0.47
LYN P07948 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1848013 0.92 CNR1 (0.53) SMN1; SMN2PKMKMT2AIMPDH2KDR
SCHEMBL1847629 0.91 CNR1 (0.55) SMN1; SMN2PKMKMT2ARIPK1KDR
SCHEMBL1848843 0.89 CNR1 (0.46) SMN1; SMN2PKMKMT2ARIPK1IMPDH2
SCHEMBL1851742 0.89 CNR1 (0.47) SMN1; SMN2PKMKMT2AIMPDH2CNR1
SCHEMBL1847240 0.88 KCNK3 (0.58) SMN1; SMN2PKMKMT2AKDRFLT1
SCHEMBL1852058 0.88 DDX3X (0.55) SMN1; SMN2PKMKMT2AIMPDH2KDR
SCHEMBL1849296 0.88 NAMPT (0.54) SMN1; SMN2PKMKMT2AROCK2ROCK1
SCHEMBL1848041 0.88 KMT2A (0.52) SMN1; SMN2PKMKMT2ARIPK1CNR1
SCHEMBL1848777 0.88 CNR1 (0.58) RIPK1IMPDH2CNR1AURKAROCK2
SCHEMBL1846752 0.87 ALDH1A1 (0.63) SMN1; SMN2KMT2ARIPK1KDRCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
US-8946250-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-03 US disclosed
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-01-02 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
US-8541575-B2 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-24 US disclosed
EP-2324008-B1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2012-05-09 EP disclosed
EP-2324008-B1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2012-05-09 EP disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-06-16 US disclosed
EP-2324008-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-25 EP disclosed
WO-2010010154-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 WO disclosed
WO-2010010154-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005150-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 SMN1; SMN2 4073/4885PKM 578/4885KMT2A 1195/4885
US-20110144068-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K3, MAP3K19, MAP3K15 SMN1; SMN2 4073/4885PKM 578/4885KMT2A 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.